Annual Total Long Term Liabilities
$4.44 M
-$296.00 K-6.24%
December 1, 2023
Summary
- As of February 7, 2025, ORMP annual total long term liabilities is $4.44 million, with the most recent change of -$296.00 thousand (-6.24%) on December 1, 2023.
- ORMP annual total long term liabilities is now -68.94% below its all-time high of $14.31 million, reached on August 31, 2017.
Performance
ORMP Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$4.29 M
-$50.00 K-1.15%
September 1, 2024
Summary
- As of February 7, 2025, ORMP quarterly total long term liabilities is $4.29 million, with the most recent change of -$50.00 thousand (-1.15%) on September 1, 2024.
- Over the past year, ORMP quarterly long term liabilities has dropped by -$158.00 thousand (-3.56%).
- ORMP quarterly long term liabilities is now -73.56% below its all-time high of $16.21 million, reached on November 30, 2016.
Performance
ORMP Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
ORMP Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.2% | -3.6% |
| 3 y3 years | - | +51.1% |
| 5 y5 years | -55.4% | -57.0% |
ORMP Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -6.2% | +15.7% | -10.1% | +51.1% |
| 5 y | 5-year | -55.4% | +15.7% | -54.1% | +51.1% |
| alltime | all time | -68.9% | >+9999.0% | -73.6% | -100.0% |
Oramed Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.29 M(-1.2%) |
| Jun 2024 | - | $4.34 M(-0.9%) |
| Mar 2024 | - | $4.38 M(-1.6%) |
| Dec 2023 | $4.44 M(-6.2%) | $4.44 M(-1.0%) |
| Sep 2023 | - | $4.49 M(-2.3%) |
| Jun 2023 | - | $4.59 M(-1.5%) |
| Mar 2023 | - | $4.66 M(-1.7%) |
| Dec 2022 | $4.74 M(+23.4%) | $4.74 M(-0.5%) |
| Sep 2022 | - | $4.76 M(+68.0%) |
| Jun 2022 | - | $2.84 M(-22.9%) |
| Mar 2022 | - | $3.68 M(-10.3%) |
| Dec 2021 | $3.84 M(-20.0%) | - |
| Nov 2021 | - | $4.10 M(-14.7%) |
| Aug 2021 | $4.80 M(-33.5%) | $4.80 M(-13.4%) |
| May 2021 | - | $5.55 M(-11.7%) |
| Feb 2021 | - | $6.28 M(-10.5%) |
| Nov 2020 | - | $7.02 M(-2.8%) |
| Aug 2020 | $7.22 M(-27.5%) | $7.22 M(-8.7%) |
| May 2020 | - | $7.91 M(-8.4%) |
| Feb 2020 | - | $8.64 M(-7.5%) |
| Nov 2019 | - | $9.34 M(-6.2%) |
| Aug 2019 | $9.96 M(-15.1%) | $9.96 M(-6.5%) |
| May 2019 | - | $10.66 M(-6.2%) |
| Feb 2019 | - | $11.36 M(+7.4%) |
| Nov 2018 | - | $10.57 M(-9.9%) |
| Aug 2018 | $11.73 M(-18.0%) | $11.73 M(-5.1%) |
| May 2018 | - | $12.37 M(-5.3%) |
| Feb 2018 | - | $13.06 M(-4.6%) |
| Nov 2017 | - | $13.68 M(-4.4%) |
| Aug 2017 | $14.31 M | $14.31 M(-4.3%) |
| May 2017 | - | $14.95 M(-4.1%) |
| Feb 2017 | - | $15.58 M(-3.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Nov 2016 | - | $16.21 M(+24.5%) |
| Aug 2016 | $13.02 M(>+9900.0%) | $13.02 M(+226.8%) |
| May 2016 | - | $3.98 M(-4.0%) |
| Feb 2016 | - | $4.15 M(>+9900.0%) |
| Nov 2015 | - | $38.00 K(+2.7%) |
| Aug 2015 | $37.00 K(+2.8%) | $37.00 K(0.0%) |
| May 2015 | - | $37.00 K(+2.8%) |
| Feb 2015 | - | $36.00 K(0.0%) |
| Nov 2014 | - | $36.00 K(0.0%) |
| Aug 2014 | $36.00 K(+16.1%) | $36.00 K(+12.9%) |
| May 2014 | - | $31.90 K(-1.5%) |
| Feb 2014 | - | $32.40 K(+1.6%) |
| Nov 2013 | - | $31.90 K(+2.9%) |
| Aug 2013 | $31.00 K(-96.4%) | $31.00 K(-87.1%) |
| May 2013 | - | $241.10 K(+0.5%) |
| Feb 2013 | - | $239.90 K(-0.2%) |
| Nov 2012 | - | $240.40 K(-72.4%) |
| Aug 2012 | $872.40 K(+442.9%) | $872.40 K(+494.3%) |
| May 2012 | - | $146.80 K(-9.4%) |
| Feb 2012 | - | $162.00 K(+0.7%) |
| Nov 2011 | - | $160.80 K(+0.1%) |
| Aug 2011 | $160.70 K(-0.8%) | $160.70 K(-0.8%) |
| May 2011 | - | $162.00 K(0.0%) |
| Feb 2011 | - | $162.00 K(0.0%) |
| Nov 2010 | - | $162.00 K(0.0%) |
| Aug 2010 | $162.00 K(+10.1%) | $162.00 K(+10.1%) |
| May 2010 | - | $147.10 K(0.0%) |
| Feb 2010 | - | $147.10 K(0.0%) |
| Nov 2009 | - | $147.10 K(0.0%) |
| Aug 2009 | $147.10 K | $147.10 K(>+9900.0%) |
| May 2009 | - | $0.00(0.0%) |
| Feb 2009 | - | $0.00 |
FAQ
- What is Oramed Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Oramed Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Oramed Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of ORMP is $4.44 M
What is the all time high annual total long term liabilities for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual total long term liabilities is $14.31 M
What is Oramed Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, ORMP annual total long term liabilities has changed by -$296.00 K (-6.24%)
What is Oramed Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of ORMP is $4.29 M
What is the all time high quarterly long term liabilities for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly total long term liabilities is $16.21 M
What is Oramed Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, ORMP quarterly total long term liabilities has changed by -$158.00 K (-3.56%)